Key Takeaways
What Is LLLT Therapy?
LLLT therapy, short for low-level laser (or light) therapy, exposes cells or tissue to low levels of red and near-infrared light to change how they function[1]. It is called low-level because its energy densities are low compared with surgical lasers used to ablate, cut or coagulate tissue[1].
Researchers have tested low-level laser therapy for pain, hair loss, cancer-treatment side effects and, more recently, depression. That last use is why it appears on mhstats.org; how many people live with a mental health condition is tracked on the any mental illness page.
The same treatment goes by several names: photobiomodulation (PBM), photobiomodulation therapy (PBMT), cold laser therapy, low-level light therapy and red light therapy. When the light is aimed at the head, studies call it transcranial photobiomodulation (t-PBM).
Is LLLT the same as red light therapy?
Largely, yes. LLLT covers red and near-infrared wavelengths delivered by either lasers or light-emitting diodes (LEDs), while "red light therapy" usually refers to consumer LED devices in the red range. The overlap shows up in regulation: one hair-growth comb cleared by the FDA in 2024 delivers LED light at 650 nm under the same product code as laser hair devices[7].
Photobiomodulation (PBM)
The use of photons at a non-thermal irradiance to alter biological activity[1]. It is the current scientific name for low-level laser (light) therapy, and it includes both laser and LED light sources.
Related Terms
Source: Avci et al., Seminars in Cutaneous Medicine and Surgery, 2013
How Does Low-Level Laser Therapy Work?
The leading explanation centers on cytochrome c oxidase, an enzyme in the mitochondria. Its light-absorption spectra closely match the spectra of the biological responses that LLLT produces[1].
Absorbed light is thought to release inhibitory nitric oxide from the enzyme, which increases electron transport, mitochondrial respiration and production of ATP, the cell's energy molecule[1]. The resulting shift in the cell's redox state activates signaling pathways tied to cell survival, proliferation, tissue repair and regeneration[1].
The mechanism is not settled. Reviewers from the Wellman Center for Photomedicine note continuing uncertainty about how incoming photons are translated into biological effects[1].
Why the dose matters
LLLT follows what researchers call a biphasic dose response: too little light can make treatment ineffective, and too much can damage tissue[1]. Trials also differ in wavelength, power, session length and number of sessions, which makes results hard to compare and helps explain why findings vary from study to study.
What Is LLLT Used For, and Does It Work?
The strongest evidence for low-level laser therapy sits in three areas: musculoskeletal pain, pattern hair loss and prevention of mouth sores during cancer treatment. Each rests on systematic reviews rather than single studies.
Neck pain
A 2009 meta-analysis in The Lancet pooled 16 randomized controlled trials with 820 patients[2]. In acute neck pain, two trials showed patients were 1.69 times as likely to report pain improvement with LLLT as with placebo[2].
In the 11 trials that used a 100-mm visual analogue scale, pain fell by 19.86 mm more than in controls[2]. Seven trials followed patients for 1 to 22 weeks after treatment ended, and the benefit held at a 22.07 mm reduction[2]. These figures come from a review published in 2009[2], and newer neck-pain trials are not included in them.
Hair loss
For androgenetic alopecia (male and female pattern hair loss), a 2026 meta-analysis covered 37 studies and 3,298 patients[3]. Pooled LLLT results showed an increase of 18.56 hairs per cm² and 10.62 µm in shaft thickness compared with sham devices[3].
Adding LLLT to minoxidil produced 11.75 more hairs per cm² than minoxidil alone[3]. Fractional lasers combined with topical agents such as minoxidil or platelet-rich plasma outperformed LLLT in the same review[3].
Oral mucositis in cancer care
The Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) recommend photobiomodulation to prevent oral mucositis and related pain in three groups: stem cell transplant patients, and head and neck radiotherapy patients with or without chemotherapy[5]. The same 2019 guideline found too little evidence to issue any guideline for treating mucositis once it has developed[5].
LLLT Evidence at a Glance
| Use | Evidence | Key finding | Year |
|---|---|---|---|
| Neck pain | Meta-analysis, 16 RCTs (820 patients) | 19.86 mm less pain on 100-mm scale | 2009 |
| Pattern hair loss | Meta-analysis, 37 studies (3,298 patients) | +18.56 hairs/cm² vs. sham | 2026 |
| Oral mucositis prevention | MASCC/ISOO guideline | Recommended for HSCT and head and neck radiotherapy | 2019 |
| Depressive symptoms | Meta-analysis, 11 RCTs (407 patients) | SMD −0.55, moderate certainty | 2024 |
| Depressive symptoms | Meta-analysis, 18 trials | Hedges' g −0.47 | 2025 |
Selected systematic reviews and guidelines on low-level laser therapy (photobiomodulation), by use[2][3][5][4][8]
1Negative SMD and Hedges' g values mean lower depression scores with photobiomodulation than with control.
2HSCT: hematopoietic stem cell transplantation. RCT: randomized controlled trial.
Sources
- •Chow et al., The Lancet, 2009
- •Alahmadi et al., Skin Appendage Disorders, 2026
- •Zadik et al., Supportive Care in Cancer, 2019
- •Ji et al., Frontiers in Psychiatry, 2024
- •Seok et al., Journal of Affective Disorders, 2025
LLLT for Depression: What the Trials Show
Depression trials use two approaches. Transcranial photobiomodulation (t-PBM) directs near-infrared light at the head, while systemic photobiomodulation (s-PBM) applies light elsewhere on the body.
A 2024 meta-analysis in Frontiers in Psychiatry pooled 11 randomized trials with 407 patients and found that PBM reduced depressive symptoms compared with controls (SMD −0.55; 95% CI −0.75 to −0.35)[4]. The authors rated the certainty of that result as moderate, and found no statistically significant effect on sleep[4].
A 2025 meta-analysis in the Journal of Affective Disorders reviewed 18 trials and found a similar pooled effect (Hedges' g −0.47; 95% CI −0.73 to −0.22)[8]. Systemic PBM outperformed transcranial PBM, laser-based devices outperformed LED-based ones, and longer treatment duration was associated with greater benefit[8].
How many LLLT sessions do depression trials use?
There is no standard course. In the 2024 analysis, the largest improvements with transcranial PBM came from 823 nm light, 30-minute sessions given fewer than 3 times a week, and more than 15 treatments in total[4].
For systemic PBM, the best results came from 808 nm light, sessions of 5 minutes or less given at least 3 times a week, and again more than 15 treatments[4]. Those are patterns across a small set of trials, not tested dosing recommendations.
What the depression evidence does not show yet
Both review teams flag the same limit. The 2024 authors write that the number of studies is small[4], and the 2025 authors call for larger trials to establish standard treatment protocols[8].
Photobiomodulation is also absent from the National Institute of Mental Health's list of brain stimulation therapies, which covers electroconvulsive therapy, repetitive transcranial magnetic stimulation (rTMS), vagus nerve stimulation, magnetic seizure therapy and deep brain stimulation[9]. Of those, rTMS is FDA-cleared for treatment-resistant depression, OCD, migraines, anxiety with depression and smoking dependence[9].
Data on how common depression and treatment-resistant depression are sit on their condition pages. Trial results for established options are covered in posts on CBT for depression and electroconvulsive therapy. Bright light therapy for seasonal affective disorder is a separate treatment that uses a light box, not red or near-infrared light applied to tissue.
Pooled reduction in depression scores with photobiomodulation vs. control, 11 randomized trials (407 patients)
A moderate effect rated as moderate-certainty evidence, drawn from a small number of trials. The authors say more studies are needed before the result can be extended.
"PBM alleviated depression (SMD = −0.55, 95% CI [−0.75, −0.35]"
Is LLLT FDA-Approved?
LLLT hair-growth devices reach the U.S. market through FDA clearance rather than approval, and each clearance covers one device for a specific use[7]. The FDA's 2024 decision on one LED hair-growth comb shows how that works[7].
The agency found the device "substantially equivalent" to legally marketed predicate devices through a 510(k) premarket notification, a pathway that does not require a premarket approval application[7]. It is a Class II device under 21 CFR 890.5500, the infrared lamp regulation, with product code OAP[7].
Its cleared indication is narrow: androgenetic alopecia in men with Norwood-Hamilton IIa to V hair loss and women with Ludwig-Savin I-1 to I-4, II-1, II-2 or frontal patterns, all with Fitzpatrick skin types I to IV[7]. A clearance for hair growth says nothing about pain, wound care or depression.
LLLT Side Effects, Safety and Insurance Coverage
Reported side effects are mild in the reviews above. In the neck-pain trials, side effects from LLLT were mild and no different from placebo[2], and in the hair-loss studies adverse events were mild and transient[3].
The biphasic dose response is the main theoretical risk: higher doses than a protocol calls for can damage tissue[1]. Trial protocols for depression also vary widely in wavelength, power and schedule, so there is no single standard course[8].
Does insurance cover LLLT?
Medicare does not cover it for several common uses. Effective October 24, 2006, the Centers for Medicare & Medicaid Services ruled infrared therapy devices not reasonable and necessary, and made infrared and near-infrared light, including monochromatic infrared energy, non-covered for peripheral sensory neuropathy, skin and subcutaneous wounds, and ulcers[6].
That national coverage determination names those conditions specifically. It does not address hair loss, oral mucositis or depression, so coverage for those uses depends on the plan.
Frequently Asked Questions
Sources & References
- Avci P, Gupta A, Sadasivam M, et al. Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. Seminars in Cutaneous Medicine and Surgery. Published 2013. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC4126803/ [Link]
- Chow RT, Johnson MI, Lopes-Martins RAB, Bjordal JM. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials. The Lancet. Published 2009. Accessed October 2026. https://doi.org/10.1016/S0140-6736(09)61522-1 [Link]
- Alahmadi M, Alghamdi S, Albyali S, et al. Lasers and energy-based devices in the treatment of androgenetic alopecia: a systematic review and meta-analysis. Skin Appendage Disorders. Published 2026. Accessed October 2026. https://doi.org/10.1159/000551411 [Link]
- Ji Q, Yan S, Ding J, et al. Photobiomodulation improves depression symptoms: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Psychiatry. Published 2024. Accessed October 2026. https://doi.org/10.3389/fpsyt.2023.1267415 [Link]
- Zadik Y, Arany PR, Fregnani ER, et al. Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Supportive Care in Cancer. Published 2019. Accessed October 2026. https://doi.org/10.1007/s00520-019-04890-2 [Link]
- Centers for Medicare & Medicaid Services. National Coverage Determination: Infrared Therapy Devices (270.6). Published 2006. Accessed October 2026. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=315&ncdver=1 [Link]
- U.S. Food and Drug Administration. 510(k) premarket notification K241342: Hair Growth Comb (SZ-23, SZ-23A). Published 2024. Accessed October 2026. https://www.accessdata.fda.gov/cdrh_docs/pdf24/K241342.pdf [Link]
- Seok JW, Kim K, Kim JU, Kim JD. Effect of photobiomodulation intervention for depressive symptoms: a systematic review and meta-analysis. Journal of Affective Disorders. Published 2025. Accessed October 2026. https://doi.org/10.1016/j.jad.2025.120413 [Link]
- National Institute of Mental Health. Brain Stimulation Therapies. National Institutes of Health. Accessed October 2026. https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies [Link]